MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/md.0000000000048627

Медицинская библиотека · Medicine · 2026

Comparative effectiveness of cholesteryl ester transfer protein (CETP) inhibitors on cardiovascular outcomes: A comprehensive Bayesian network meta-analysis and network meta-regression.

Khalil Ibrahim, Islam M Rafiqul, Promi Sunjida Amin, Joy Arindam Das, Sayed Md Abu, Acharjee Durjoy, Al-Shammari Ali Saad, Rahman Mohd Turzo, Abrar Sakib, Bin Jamil Ta-Seen, Taseen Malaika, Biswas Suborna, Mifty Sumaya Khan, Al-Badri Sajjad Ghanim, Debnath Avijit, Hossain Md Imran, Akter Mst Mahmuda

СтатьяNetwork Meta-AnalysisСравнительное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Cardiovascular disease remains the leading cause of mortality worldwide, with residual cardiovascular (CVS) risk remaining high despite pharmacological interventions. Cholesteryl ester transfer protein (CETP) inhibitors have shown promise in improving lipid profiles, but their comparative effectiveness in reducing CVS outcomes remains unclear. This network meta-analysis and network meta-regression aimed to evaluate the comparative effectiveness of CETP inhibitors (Evacetrapib, Anacetrapib, Dalcetrapib, and Torcetrapib) on CVS outcomes, including CVS mortality, all-cause mortality, major adverse cardiovascular events, myocardial infarction, need for revascularization, and stroke.

METHODS

A Bayesian network meta-analysis was conducted, incorporating data from 10 randomized controlled trials with 84,134 patients diagnosed with cardiovascular disease or at high risk. We compared various CETP inhibitors for their effectiveness in reducing CVS events. Network meta-regression was used to assess the impact of covariates such as age, sex, and baseline lipid levels.

RESULTS

Evacetrapib ranked highest for CVS mortality (relative risk [RR]: 0.92, 95% credible interval [CrI]: 0.39-1.87; Surface Under the Cumulative Ranking Curve [SUCRA]: 71.91%) and Anacetrapib for major adverse cardiovascular events (RR: 0.40, 95% CrI: 0.07-1.06; SUCRA: 84.25%). Dalcetrapib showed favorable effects on all-cause mortality (RR: 0.72, 95% CrI: 0.16-1.42; SUCRA: 67.51%) and stroke (RR: 0.75, 95% CrI: 0.41-1.26; SUCRA: 83.03%). Anacetrapib had the highest rank in reducing myocardial infarction (RR: 0.83, 95% CrI: 0.46-1.15; SUCRA: 86.06%).

CONCLUSIONS

This analysis suggests that Evacetrapib and Anacetrapib are the most effective CETP inhibitors for improving CVS outcomes, with Dalcetrapib showing beneficial effects in certain outcomes. Further studies are needed to confirm these findings.

Для цитирования: Khalil Ibrahim, Islam M Rafiqul, Promi Sunjida Amin, Joy Arindam Das, Sayed Md Abu, Acharjee Durjoy, Al-Shammari Ali Saad, Rahman Mohd Turzo, Abrar Sakib, Bin Jamil Ta-Seen, Taseen Malaika, Biswas Suborna, Mifty Sumaya Khan, Al-Badri Sajjad Ghanim, Debnath Avijit, Hossain Md Imran, Akter Mst Mahmuda. Comparative effectiveness of cholesteryl ester transfer protein (CETP) inhibitors on cardiovascular outcomes: A comprehensive Bayesian network meta-analysis and network meta-regression.. Medicine. 2026. DOI: 10.1097/md.0000000000048627.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.